- Home
- CRDF vs AQST Comparison
CRDF vs AQST Comparison
Compare CRDF & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- AQST
- Stock Information
- Founded
- CRDF 1999
- AQST 2004
- Country
- CRDF United States
- AQST United States
- Employees
- CRDF N/A
- AQST N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- CRDF Health Care
- AQST Health Care
- Exchange
- CRDF Nasdaq
- AQST Nasdaq
- Market Cap
- CRDF 288.7M
- AQST 274.4M
- IPO Year
- CRDF N/A
- AQST 2018
- Fundamental
- Price
- CRDF $4.00
- AQST $2.84
- Analyst Decision
- CRDF Strong Buy
- AQST Strong Buy
- Analyst Count
- CRDF 4
- AQST 7
- Target Price
- CRDF $12.00
- AQST $10.57
- AVG Volume (30 Days)
- CRDF 1.2M
- AQST 1.5M
- Earning Date
- CRDF 05-01-2025
- AQST 03-05-2025
- Dividend Yield
- CRDF N/A
- AQST N/A
- EPS Growth
- CRDF N/A
- AQST N/A
- EPS
- CRDF N/A
- AQST N/A
- Revenue
- CRDF $683,000.00
- AQST $57,561,000.00
- Revenue This Year
- CRDF N/A
- AQST N/A
- Revenue Next Year
- CRDF N/A
- AQST $35.72
- P/E Ratio
- CRDF N/A
- AQST N/A
- Revenue Growth
- CRDF 39.96
- AQST 13.80
- 52 Week Low
- CRDF $2.01
- AQST $2.24
- 52 Week High
- CRDF $6.42
- AQST $6.23
- Technical
- Relative Strength Index (RSI)
- CRDF 48.99
- AQST 48.60
- Support Level
- CRDF $3.52
- AQST $2.45
- Resistance Level
- CRDF $4.42
- AQST $3.06
- Average True Range (ATR)
- CRDF 0.38
- AQST 0.22
- MACD
- CRDF -0.04
- AQST 0.02
- Stochastic Oscillator
- CRDF 44.44
- AQST 63.93
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.